Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.49, $0.02 better than the analyst estimate of $1.47. Revenue for the quarter came in at $550.71 million versus the consensus estimate of $553.37 million.

GUIDANCE:

Amedisys sees FY2021 EPS of $6.25-$6.47, versus the consensus of $6.31. Net service revenue is anticipated to be in the range of $2.275 billion to $2.315 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.